Congresul ROMTRANSPLANT

Mr. Oniscu is a consultant transplant surgeon at the Royal Infirmary of Edinburgh and Honorary Reader at the University of Edinburgh. He is involved in liver, kidney and pancreas transplantation and is the lead clinician for the living donor kidney transplant programme. He is also the led clinician for novel perfusion and preservation technologies in transplantation in Edinburgh.

He has a strong research activity with particular focus on transplant outcomes, organ perfusion and reconditioning and optical sensing. He is the recipient of the NRS Career Research Fellowship and an MRC confidence in concept award for technological developments relating to normothermic perfusion. Mr. Oniscu is associated with the Liver stem cells and regeneration research group at the Centre for Regenerative Medicine Edinburgh. He is a lead investigator in the NIHR Access to Transplantation and Transplant Outcomes study, the UK NHSBT service evaluation of normothermic regional perfusion in DCD donors and the MRC study investigating the regenerative capacity of liver ductular cells. He has received more than £4.5 mil in research funding.

Mr. Oniscu is Secretary of the European Society for Organ Transplantation and chairs the Research, Innovation and Novel Technologies Advisory Group at NHS Blood and Transplant.

He has authored more than 65 papers and 12 book chapters and is the editor of Abdominal Organ Retrieval and Transplantation Bench Surgery (Wiley) and Springer Atlas of Transplantation Surgery (in press).

National and international scientific societies:

Romanian Society of Surgery: President 2006-2008;

Romanian Association of Transplantation (Romtransplant): President 1998- 2018;

Romanian Society of Endoscopic Surgery and other surgical techniques (ARCE): President 2002-2006;

Romanian Association of Hepato‐Biliary‐Pancreatic Surgery and Liver Transplantation: President 2006 – 2017;

European Surgical Association (ESA): Member (2007), President 2018-2019;

European Board of Surgery- Transplant Division (2009) and Hepato-Bilio-Pancreatic Surgery Division (2013);

European Society of Organ Transplantation (ESOT): Member;

International Association of Surgeons and Gastroenterologists (IASG): Member of Executive Committee (2002); Vice President- since 2016;

American College of Surgeons (FACS): Fellow (2005);

Romanian Academy of Medical Sciences Bucharest (Romania): Member (1999), President 2011-Present;

Romanian Academy: Corresponding Member (2013);

Federation of European Academies of Medicine (FEAM): Vice-president 2014- 2017;

Académie Nationale de Médecine France: Membre correspondant étranger ( 2013);

Académie Nationale de Chirurgie (France): Associe étranger (2003).

Editorial activities: Member of Editorial Board

• Hepatogastroenterology: Editor-in-chief (2011-2012), Senior Honorary Editor ( 2013);
• Chirurgia (Buc) (The Romanian Journal of Surgery): Editor-in-Chief (2004-2013);
• Langenbeck’s Archives of Surgery: Associate Editor;
• Journal of Gastrointestinal and Liver Disease: Member of the Editorial Board;
• Surgery, Gastroenterology and Oncology: Vice-Editor in Chief.

Visiting Professor

• Karolinska University in Stockholm (2010);
• University of Belgrade, School of Medicine (2018).

Visiting Speaker

• Grand Rounds AKH Vienna, “The surgical treatment of the metastatic colo-rectal cancer” (2015);
• Universitätsklinikum Hamburg-Eppendorf- “Central pancreatectomy” (2015);
• Weekly Surgical and Gastroenterological Grand Rounds- Borel-Staehelin-Lecture “How to increase the number of donors in a liver transplant program” – University of Zürich (2014).

Key Note Speaker

• European Congress of Coloproctology: BJS lecture-“Metastatic CRC – what about the primary?” Vienna (2012).

Luciano Potena, graduated in Medicine in 1997, completed his clinical fellowship in Cardiology in 2001, and earned a PhD degree in 2005 at the University of Bologna, Italy. He improved his scientific education at the Department of Experimental Cardiology of Utrecht University, The Netherlands (1999), and at the Cardiology Division of Stanford University, California (2003-05). He currently holds the position of Director of the Heart Failure and Transplant Unit of the IRCCS Bologna Academic Hospital.

Dr Potena has been involved in heart transplant and advanced heart failure since his MD thesis discussion in 1997. His research path was focused on prognostic stratification of advanced heart failure, development of cardiac allograft vasculopathy, CMV infection, complications of immunosuppressive therapy after heart transplant, and antibody mediated rejection. On these topics, he co-authored over 150 full papers in peer-reviewed journals, several book chapters, and he has been involved in the design and conduction of national multicenter studies on immunosuppressive therapy, and co-authored international guidelines in the field of heart transplantation and advanced heart failure.

His leadership career in ESOT started in 2013 when he was appointed chair of the new cardiothoracic section ECTTA. He was then elected as treasurer in 2015, co-chaired the ESOT congress 2021, and is currently the president of ESOT.

He is a reviewer for several medical journals, and is currently section editor of the Journal of Heart and Lung Transplantation.

Vizualizaţi CV-ul Prof. Dr. Adrian COVIC.

His research interests include clinical and experimental topics in kidney transplantation and immunobiology with an emphasis on various aspects of immune regulation and optimization of immunosuppressive drug therapy.

He has initiated and coordinated a number of clinical trials regarding the optimal use of immunosuppressive drugs after kidney transplantation. During recent years he has served as one of the leads of the ERACODA Working group (Registry of COVID-19 in kidney patients) and one of the PIs of the RECOVAC consortium (studies on vaccination against COVID-19 in kidney patients).

He is the current chair of the DESCARTES Working Group of the European Renal Association (Descartes Working Group | ERA (era-online.org)).

Between 2009 and 2011 he was a postdoc fellow in the Lymphocyte Interaction Lab directed by Dr Facundo Batista in London Research Institute (UK). Since 2012 he holds a tenure position in the Department of Nephrology, Transplantation and Clinical Immunology of Edouard Herriot Hospital in Lyon (France) and he is the head of a research group at the INSERM U1111 aiming at Establishing new Strategies to Prevent Rejection In Transplantation. 

Olivier Thanaut has published >150 peer reviewed articles and has given >200 invited conferences all over the world. He is currently the treasurer of ESOT and the president of the scientific committee of the French speaking society of transplantation.

She joined the MD Anderson faculty in 2006. Dr. Loghin maintains a very busy clinical practice, and provides expert consultative inpatient services. She currently serves as the Department of Neuro-Oncology Residency Program Director. Dr. Loghin collaborates closely with the Neuro-psychology section in developing new therapeutic strategies for cancer-related cognitive dysfunction. As part of MDACC CARTOX Cell Therapy Group, Dr. Loghin was actively involved in developing national guidelines for asessment and management of CAR T cell induced neurotoxicity.

Meet Monica Loghin, M.D.

Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Residency Program Director, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests
Dr. Loghin’s research interests are focused on neurological complications related to cancer treatment, particularly neurological and cognitive deficits induced by cancer therapy. She is collaborating closely with the Neuropschylogy Section in developing new therapeutic strategies for cancer related cognitive dysfunction.

Honors & Awards
2011 Nominated for Gerald P. Bodey Award for Excellence in Education, University of Texas MD Anderson Cancer Center.

He is board certified by the American Board of Internal Medicine in Internal Medicine, Cardiovascular Diseases, Nuclear Cardiology, Cardiac Computed Tomography and Echocardiography. Dr. Loghin is a seasoned academic clinician, with more than 30 years experience in teaching cardiology trainees, and with a very large clinical practice with UT Physicians. He also serves as a reviewer for Circulation, Journal of the American Heart Association, Journal of Nuclear Medicine and American Heart Journal.

Dr. Loghin pioneered the field of interventional imaging, and participated as an investigator in seminal trials involving management of structural heart disease. He is currently responsible for developing the cardiac computed tomography service with Memorial Hermann Hospital, the main teaching facility for UTHealth McGovern Medical School.

Research Interests

Cardiac computed tomography: coronary physiology (FFR and myocardial perfusion), chest pain management using cardiac CTA techniques, imaging of complex structural heart disease.

Echocardiography: advanced diagnostic imaging of valvular heart disease, imaging planning and guidance of transcatheter interventions for complex structural heart disease.

Honors & Awards

Cardiovascular Medicine Faculty of the Year: 2009, 2010, 2011, 2012.